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HMBAinduces activation of a caspase-independent cell death pathway to
overcome P-glycoprotein-mediated multidrug resistance
AstridA. Rueﬂi, Mark J. Smyth, and Ricky W. Johnstone
Multidrug resistance (MDR) is often char-
acterizedbytheexpressionofP-glycopro-
tein (P-gp), a 170-kd ATP-dependent drug
efflux protein. As well as effluxing xeno-
toxins, functional P-gp can confer resis-
tance to caspase-dependent apoptosis
induced by a range of different stimuli,
including Fas ligand, tumor necrosis
factor, UV irradiation, and serum starva-
tion. However, P-gp-positive cells remain
sensitive to caspase-independent death
induced by cytotoxic T-cell granule pro-
teins, perforin, and granzyme B. It is,
therefore, possible that agents that in-
duce cell death in a caspase-independent
manner might circumvent P-gp-mediated
MDR. We demonstrated here that hexa-
methylene bisacetamide (HMBA) induced
equivalent caspase-independent cell
death in both P-gp-positive and -negative
cell lines at concentrations of 10 mmol/L
and above. The HMBA-induced death
pathway was marked by release of cyto-
chrome c from the mitochondria and
reduction of Bcl-2 protein levels. In addi-
tion,weshowthatfunctionalP-gpspeciﬁ-
cally inhibits the activation of particular
caspases, such as caspases-8 and -3,
whereas others, such as caspase-9, re-
main unaffected. These studies greatly
enhanceourunderstandingofthemolecu-
lar cell death events that can be regulated
by functional P-gp and highlight the
potential clinical use of drugs that func-
tion via a caspase-independent pathway
for the treatment of MDR tumors. (Blood.
2000;95:2378-2385)
r 2000 by The American Society of Hematology
Introduction
Multidrug resistance (MDR) is a major clinical problem in treating
human cancer and is often characterized by the expression of the
MDR1 gene product, P-glycoprotein (P-gp).1 A member of the
adenosine triphosphate-binding cassette transporter family, P-gp
has traditionally been thought to confer resistance to chemotoxins
by actively effluxing them from the cell.2,3 However, recent reports
by our group and others4-6 have indicated that, in addition to its role
as an efflux pump, P-gp regulates programmed cell death mediated
by antineoplastic agents, serum starvation, UV irradiation, and
ligation of the cell surface death receptors Fas and tumor necrosis
factor (TNF) receptor. Common to these diverse apoptotic stimuli
is their dependence on the activation of caspases to initiate cell
death. We, therefore, hypothesized that the successful treatment of
P-gp1 MDR tumors might be enhanced using chemotherapeutic
agents that can function in absence of caspase activation.
There are now at least two molecular pathways leading to
caspase-dependent apoptosis (Figure 1). The best-deﬁned pathway
involves ligation of death receptors, typically members of the TNF
superfamily such as Fas and TNF receptor, at the cell surface
resulting in sequential activation of proximal caspases such as
caspase-8 and downstream effector caspases such as cas-
pase-3.7-9
The second, less well-deﬁned caspase-dependent pathway in-
volves the disruption of the mitochondrial transmembrane potential
(DCm) and the release of mitochondrial proteins such as cyto-
chrome c10-12 and apoptosis-inducing factor.13 Cytochrome c coop-
erates with dATP and Apaf-1 to induce the activation of caspase-9
that can cleave and activate caspase-3.14,15 Importantly, release of
mitochondrial cytochrome c is inhibited by anti-apoptotic members
of the Bcl-2 family, such as Bcl-2 and Bcl-XL, and promoted by
pro-apoptotic members such as Bid, Bax, and Bak.11,16-18
In addition to caspase-dependent apoptosis, there is now
sufficient evidence to suggest that apoptosis can occur in the
absence of active caspases. Caspase-independent cell death has
been shown to be induced by perforin and granzyme B,19 anti-
CD2,20 and the protein kinase C inhibitor staurosporine.20,21 In the
absence of caspase activation, cytoplasmic events related to
apoptosis, such as cell shrinkage, cytoplasmic condensation, and
lossofmitochondrialmembraneintegrityandexposureofphospha-
tidylserine, are still induced by these stimuli.19-21 Caspase-
independent cell death has been shown to be inhibited by Bcl-2,22,23
suggesting that a loss of mitochondrial function is central to this
death process.
Work by our group and others4-6 has demonstrated that func-
tional P-gp can confer resistance to a wide range of caspase-
dependent apoptotic stimuli, such as ligation of cell-surface death
receptors, serum starvation, and UV irradiation. We demonstrated
thatfunctionalP-gp-inhibitedactivationofcaspase-3followingFas
ligation and that this inhibitory effect could be reversed using P-gp
antagonists, such as speciﬁc anti-P-gp monoclonal antibodies
(mAbs) or the pharmacological inhibitor verapamil.4 Many chemo-
therapeutic drugs, such as doxorubicin and vincristine, function in
a caspase-dependent manner;4,5 therefore, P-gp may play a dual
role in regulating cell death induced by these stimuli (i) by
From the Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.
Submitted September 13, 1999; accepted December 2, 1999.
Supported by project grants from the NH&MRC and the Anti-Cancer
Council, Victoria.
R.W.J. is an R.D. Wright Fellow of the National Health and Medical Research
Council of Australia (NH&MRC); M.J.S. is a Principal Research Fellow,
NH&MRC; and A.A.R. is currently supported by the Dr Laurence LeWinn
Post-graduate Research Scholarship.
Reprints: Ricky W. Johnstone, The Austin Research Institute, Austin Hospital,
Studley Rd, Heidelberg 3084, Victoria, Australia; e-mail: r.johnstone@
ari.unimelb.edu.au.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’in accordance with 18 U.S.C. section 1734.
r 2000 by TheAmerican Society of Hematology
2378 BLOOD, 1APRIL 2000 x VOLUME 95, NUMBER 7
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From removing the toxins from the cell and (ii) by inhibiting the
activation of caspases. Importantly, P-gp does not offer cells
protection from death induced by lytic concentrations of the
pore-forming protein perforin5 or by a combination of granzyme B
and sublytic concentrations of perforin,4,5 which together can
function in a caspase-independent manner.4,5,19 We, therefore,
reasoned that drugs that were not P-gp substrates and could mediate
caspase-independent cell death might be clinically useful for the
treatment of MDR. Given that caspase-independent cell death is
comparatively poorly understood, and few cell-death stimuli have
been shown to function in a caspase-independent manner, we
undertook a search for a chemotherapeutic agent that could kill
P-gp-expressing cells by this mechanism.
Hexamethylene bisacetamide (HMBA) is a hybrid polar com-
pound that can induce terminal differentiation of transformed
cells24,25 and has been used clinically to treat patients with acute
myeloid leukemia and myelodysplastic syndrome.26 Terminal dif-
ferentiation induced by HMBAcorrelates with a dramatic decrease
in cdk4-dependent kinase activity and hypophosphorylation of the
retinoblastoma tumor suppressor protein.27 Interestingly, HMBA
also induced activation of the JAK/STAT signal transduction
pathway via JAK2 and STAT5 but suppressed activation via SHC
and GRB2.28 Although hypophosphorylation of retinoblastoma
tumor suppressor protein and the related family member p107 is
clearly involved in causing cells to arrest in the G1 phase of the cell
cycle, it is unclear what role HMBA-mediated modulation of
signaling pathways triggered by stimulation of cytokine and/or
growth factor receptors plays in inducing cellular differentiation.A
previous report29 indicated that HMBA could induce cell death in
P-gp-expressing cells; however, no data were shown and the
mechanism of cell death in P-gp-expressing cells was not explored.
We report here that HMBA can induce cell death in P-gp-
expressing human tumor cells, and, in agreement with our previous
reports, HMBA induced activation of caspase-3 in P-gp- but not
P-gp1 cells. However, in the absence of caspase activation, HMBA
could still induce cell death that was marked by the caspase-
independent release of cytochrome c from the mitochondria to the
cytosol and a reduction in Bcl-2 levels. Importantly, overexpres-
sion of Bcl-2 inhibited HMBA-mediated cell death. Furthermore,
we illustrate that P-gp-expressing cells have a reduced capacity to
activate caspases involved in death receptor-mediated apoptosis,
such as caspases-8 and-3, but not caspase-9, which is activated
following release of cytochrome c from the mitochondria.
Materials and methods
Cell culture
The acute T-cell leukemia cell line, CEM-CCRF, and its doxorubicin-
selected and -resistant P-gp1-derived line CEM-A71 have been previously
described.30 Colon carcinoma LoVo cell line and LoVo resistant to
Adriamycin (LoVo-adr) have been previously described.31 K562 and
vincristine selected P-gp1 KVIN2000 cells were kindly provided by Greg
Woods, University of Tasmania, Hobart,Australia. CEM and FDC-P1 cells
overexpressing human Bcl-2, Bid, and Bid-Bcl-2 were a gift from David
Huang (Walter and Eliza Hall Institute, Melbourne, Victoria).All cells were
grown in RPMI medium 1640 supplemented with 10% (vol/vol) fetal calf
serum, 2 mmol/L glutamine, 100 units/mL of penicillin, and 100 µg/mL of
streptomycin (GIBCO, Grand Island, NY), with the exception of FDC-P1
cell lines that were grown in DME with the additives listed above and
interleukin-3 (IL-3). Cells were cultured for 4-72 hours with 0-30 mmol/L
HMBA (Sigma, St. Louis, MS), 10-100 ng/mL doxorubicin, 5-100 ng/mL
vincristine, or 100-500 ng/mL anti-Fas antibody clone CH-11 (Upstate
Biotechnology, Lake Placid, NY). Doxorubicin and vincristine were
obtained from Phillip Kantharidis, Peter MacCallum Cancer Institute, East
Melbourne, Australia. To inhibit the activation of caspases, cells were
pretreated for 30 minutes with peptidyl ﬂuoromethylketones (ZFA-fmk,
ZVAD-fmk, or Z-YVAD-fmk) (Enzyme System Products, Dublin, CA)
(ﬁnal 0-40 µmol/L).
Viability assays
Cells were cultured at 2 3 105 cells/mL in the presence or absence of cell
death stimuli for varying times. Trypan blue exclusion assays were
performed as previously described.5 In all assays, 150-300 cells were
counted for each data point, and data were calculated as the mean 6 SE of
triplicate samples and are representative of at least three separate assays.
The number of apoptotic or dead cells (blue cells) was expressed as a
percentage of the total cell number.
Clonogenic assays
Colony assays were performed on cells treated for 24-72 hours with various
apoptotic stimuli as previously described.5
DNA fragmentation
Cells (1 3 106) were washed with phosphate-buffered saline (PBS) and
pelleted by centrifugation. Genomic DNA was prepared as previously
described.32 DNA(10-15 µg) was run on a 2% agarose gel for 2 hours. The
gel was stained in ethidium bromide (1 µg/mL) for 15 minutes and washed
for 1 hour in water.
TUNEL assay
Cells (2 3 105) treated with various apoptotic stimuli were assayed by
TUNEL(Boehringer Mannheim) as previously described.33
Propidium iodide (PI) staining
Cells (2 3 105) treated with various apoptotic stimuli were washed with
PBS and ﬁxed in 50% ice-cold EtOH/PBS for 20 minutes on ice. Cells were
washed with PBS and incubated in PI solution (69 mmol/L PI/388 mmol/L
Na Citrate/100 µg/mL Rnase A) for 15 minutes at 37°C. Cells were
immediately analyzed by FACscan ﬂow cytometer (Becton Dickinson).
Western blot analysis
Cells (2 3 105) were lysed in 50 mLof ice-cold Nonidet P-40 lysis buffer as
previously described.4 Protein determinations were performed using the
Bradford reaction.34 Proteins (10-20 µg) were separated on SDS-12% or
SDS-15% polyacrylamide gels and electroblotted onto nylon membranes.
Figure 1. Caspase-dependent and caspase-independent mechanisms of cell
death. Caspase-dependent apoptosis induced by death-receptor ligation can act
independently of the mitochondria and is inhibited by P-glycoprotein (P-gp) at the
level of caspase-8 and caspase-3 activation. In contrast, some cytotoxic drugs induce
the disruption of mitochondrial membrane potential (DCm), release of cytochrome c,
and subsequent activation of caspase-9. In addition, disruption of DCm can also lead
to caspase-independent cell death that is not inhibited by P-gp.
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tories, Lexington, KY), anti-human FLICE mAb (gift from Marcus Peter,
University of Heidelberg, Germany), anti-human caspase-9 (gift from
Xiaodong Wang, Howard Hughes Medical Institute and Department of
Biochemistry, University of Texas Southwestern Medical Center, Dallas,
TX; and Douglas Green, La Jolla Institute forAllergy and Immunology, San
Diego, CA), anti-human Bcl-2 mAb (David Huang, WEHI, Melbourne
Australia), anti-human PARP (Boehringer Mannheim), or anti-human
a-tubulin mAb (Sigma, St. Louis, MO) and visualized by enhanced
chemiluminescence (Amersham, UK).
Cytochrome c release
Cells (2 3 107) treated for 3 days with 10 or 15 mmol/L HMBA were
washed twice in ice-cold PBS. Cytosolic lysates were prepared as previ-
ously described.21 Cytosolic proteins were separated on a SDS-15%
polyacrylamide gel and transferred onto nylon membranes. Blots were
probed with anti-human cytochrome c mAb (PharMingen, San Diego, CA;
clone 7H8.2C12) and visualized as above. The same blots were reprobed
with anti-a-tubulin to determine that equal amounts of protein were present
in each well. Cytospin slides of CEM cells treated for 24-72 hours with 10
and 15 mmol/LHMBAin the presence or absence of 40 µmol/LZVAD-fmk
or ZFA-fmk were stained for cytochrome c as previously described35 and
visualized by confocal microscopy.
Immunoﬂuorescence and analysis of apoptotic nuclei
Cytospin slides of 1 3 105 cells treated for varying times with 0-20 mmol/L
HMBAwere ﬁxed in EtOH/acetic acid (6/1) (vol/vol) for 5 minutes. Slides
were stained with 10 ng/mL Hoechst 33 258 for 5 minutes and washed
twice in citrate buffer pH 5.5. Cells were visualized by confocal and
ﬂuorescence microscopy, and 450-500 cells per sample were counted and
apoptotic nuclei scored.
Results
P-gp does not protect tumor cells from HMBA-mediated death
P-gp1 and P-gp- CEM, LoVo, and K562 cell lines were used to
examine the effects of HMBAon cell viability. CEM cell lines were
cultured in the presence of 0-20 mmol/L HMBA for 24-72 hours,
and cell death was initially determined by trypan blue exclusion
assays. HMBA-induced equivalent cell death in a dose- and
time-dependent manner in both P-gp1 and P-gp- CEM (Figure 2A)
and LoVo (Figure 2B) cell lines. However, the effects of HMBAon
cell viability were cell speciﬁc. P-gp1 and P-gp- K562 cells treated
with HMBA did not die (Figure 2C), but rather underwent G1 cell
cycle arrest as measured by PI staining for DNA content (data not
shown), consistent with previous reports24 that HMBA induces
growth arrest in this erythroid cell line. As controls for drug
sensitivity, P-gp- CEM, LoVo, and K562 cells were effectively
killed by the chemotherapeutic agent, doxorubicin (100-200 ng/
mL), whereas P-gp1 cells were resistant to doxorubicin-induced
death (Figure 2A-C). To evaluate viability by a more sensitive
method, and to correlate trypan blue staining with cell death,
clonogenic assays were employed. HMBA treatment of P-gp1 or
P-gp- CEM cells resulted in a dose-dependent decrease in colony
formation (Figure 2D). P-gp1 CEM cells survived doxorubicin-
mediated apoptosis, whereas P-gp- CEM cells were sensitive to
doxorubicin-induced cell death.
HMBA induces nuclear morphological changes consistent
with apoptosis
To characterize the biochemical and morphological changes in
cells undergoing HMBA-induced cell death, CEM cells were
cultured in the presence or absence of 10 mmol/LHMBAfor 24-48
hours and subsequently assayed for classical hallmarks of apopto-
sis, such as chromatin condensation, DNAladdering, and cleavage
of the DNArepair enzyme PARP.36-38Treatment of P-gp1 and P-gp-
CEM cells with HMBA resulted in DNA fragmentation as evi-
denced by the formation of DNA ladders (Figure 3A) and by
TUNEL staining (Figure 3B). In addition, CEM cells treated with
HMBA and subsequently stained with Hoechst 33 258 displayed
chromatin condensation indicative of apoptotic nuclei (Figure 3C).
Apoptotic nuclei appeared within 6 hours after treatment with 10
mmol/L HMBA, and the number of apoptotic cells increased with
time (.15% at 24 hours, .25% at 48 hours). In addition, PARP
was cleaved in a dose-dependent manner in both P-gp1 and P-gp-
CEM cells (Figure 3D).
Interestingly, P-gp1 cells typically displayed signiﬁcantly less
chromatin condensation and DNA fragmentation than P-gp- cells
following HMBA treatment (Figure 3A-C). This ﬁnding is consis-
tent with our previous studies showing that P-gp1 cells were less
sensitive to those nuclear apoptotic events that occur following
caspase activation.4,5
HMBA can induce caspase-independent cell death
As HMBA induced many of the cell death events indicative of
caspase-dependent apoptosis, we sought to determine whether
this chemotherapeutic agent could still kill CEM cells in the
absence of caspase activation.To examine if HMBA-induced death
was caspase-independent, CEM cells were pretreated with the
universal caspase inhibitor ZVAD-fmk or the control inhibitor
ZFA-fmk and then cultured for 48 hours with 10 mmol/L HMBA.
P-gp1 and P-gp- CEM cells treated with HMBA in the presence of
ZVAD-fmk displayed equivalent cell death when compared with
controls treated with HMBAalone, indicating that HMBA-induced
cell death was caspase-independent (Figure 4A). By comparison,
P-gp- CEM cells treated for 48 hours with 5 ng/mL vincristine in
the presence of ZVAD-fmk were protected from cell death,
Figure 2. Hexamethylene bisacetamide (HMBA)-induced cell death in P-
glycoprotein (P-gp) cell lines. P-gp1 (A7) and P-gp- (CCRF) CEM cells (A), P-gp1
(LoVo-adr) and P-gp- (LoVo) LoVo colon carcinoma cells (B), and P-gp1 (KVIN) and
P-gp- (K562) K562 myeloid cells (C) were cultured for 72 hours with 0-20 mmol/L
HMBAor 100-200 ng/mL doxorubicin. Cells were counted at 72 hours by trypan blue
exclusion as described in ‘‘Materials and methods.’’ (D) After 3 days in culture with
0-20 mmol/L HMBAor 100 ng/mL doxorubicin,A7 and CCRF cells were plated out in
soft agar. Colonies were scored after 2 weeks in culture as described in Materials and
methods section.
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cell death was dependent on active caspases (Figure 4A). As
expected, P-gp1 CEM cells were resistant to caspase-dependent
cell death induced by vincristine (Figure 4A). These control
experiments with vincristine as the apoptotic mediator also serve to
conﬁrm the effectiveness of the caspase inhibitory ZVAD-fmk
peptide over the 48-hour time course of the experiment. These data
were conﬁrmed by clonogenic assays with equivalent HMBA-
induced cell death in the presence of ZVAD-fmk and ZFA-fmk
(data not shown).
Although HMBA-induced death was found to be caspase-
independent, ZVAD-fmk inhibited chromatin condensation (Figure
4B), DNA fragmentation (data not shown), and cleavage of the
caspase substrate PARP (Figure 4E) in HMBA-treated cells. These
data indicate that, although HMBA induced equivalent caspase-
independent cell death in P-gp1 and P-gp- CEM cells (Figures 2
and 3), most nuclear events associated with this form of apoptosis
remained caspase-dependent (Figure 4B). Furthermore, the fact
that ZVAD-fmk completely abrogated PARP cleavage indicates
that caspases were not active under these conditions. Thus,
although HMBAis capable of inducing cell death in the absence of
caspase activity, HMBAdoes instigate activation of some caspases
independent of P-gp expression.
HMBA induces activation of caspase-9
As we had previously determined that caspase-3 activation was
inhibited in P-gp1 cells, we were surprised to ﬁnd that the caspase
substrate PARP was equivalently cleaved in both P-gp1 and P-gp-
cells. Therefore, we determined which caspases were activated
following HMBA treatment and potentially responsible for the
observed PARP cleavage and apoptotic nuclear events. Caspase-3
was activated by HMBA in P-gp- cells (Figure 5A, top left panel)
but not in P-gp1 cells (Figure 5A, top right panel). Similarly, and
consistent with our earlier report,4 caspase-3 was activated follow-
ing Fas ligation only in P-gp- but not P-gp1 CEM cells (Figure 5B,
top panel). Inhibition of caspase-3 activation in P-gp-expressing
CEM cells can be reversed by the P-gp inhibitor verapamil and
mAbs to P-gp4, indicating that these cells do not express a mutated
form of caspase-3 but rather that expression of functional P-gp
inhibits caspase-3 activation. We then investigated whether key
‘‘activator’’ caspases upstream of caspase-3, such as caspase-8,
typically involved in receptor-mediated cell death,7-9 or caspase-9,
central to the mitochondrial death pathway,14,15 were activated
during HMBA-induced death. Western analyses for caspases-8 and
-9 were performed on lysates from cells treated with HMBA
(Figure 5A). Even after 72 hours, no evidence of caspase-8
activation was observed in either P-gp1 or P-gp- cells treated with
as much as 15 mmol/L HMBA (Figure 5A, middle panel).
However, treatment with anti-Fas mAb resulted in a reduction in
pro-caspase-8 and the appearance of active caspase-8 in P-gp- but
not P-gp1 CEM cells (Figure 5B, middle panel), demonstrating for
the ﬁrst time that P-gp can inhibit caspase-8 activation. As with
caspase-3, caspase-8 could be activated in Fas-ligated P-gp1 CEM
cells following treatment with either speciﬁc antagonistic anti-P-gp
mAbs or with verapamil (data not shown). In contrast, HMBA
induced the typical cleavage and auto-activation39 of caspase-9 to
p37, p15, and p13 subunits in a dose-dependent manner in both
P-gp1 and P-gp- CEM cells (Figure 5A, bottom panel), indicating
Figure 3. Hexamethylene bisacetamide (HMBA)-induced nuclear damage indicative of apoptosis. (A) CCRF and A7 CEM cells were untreated or cultured for 48 hours
with 10 mmol/L HMBA or for 4 hours with 100 ng/mL anti-Fas antibody (CH-11). Genomic DNA was extracted and run on a 2% agarose gel. CCRF and A7 CEM cells were
treated for 48 hours with 10 mmol/L HMBA and assayed by TUNEL for DNA fragmentation as denoted by an increase in mean channel ﬂuorescence (B) and Hoechst 33 258
staining (C) for chromatin condensation. The percentage of TUNEL-positive cells are shown above each histogram, and cells displaying chromatin condensation are indicated
by an arrow. Lysates from CCRF andA7 cells treated for 72 hours with 0-20 mmol/LHMBAwere separated by SDS-PAGE, and Western blots were performed using polyclonal
anti-PARP antibody (D). The active form of PARP migrates as a 118-kD protein and cleaved to an inactive form of approximately 89 kd.
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mitochondrial membrane might be functioning in HMBA-
mediated cell death and that the activation of this caspase is not
affected by P-gp expression.
HMBA stimulates the loss of Bcl-2 and release of mitochondrial
cytochrome c
Activation of caspase-9 can be mediated via the interaction of
mitochondrial cytochrome c with Apaf 1 in the presence of
dATP/ATP in the cytosol.14,15 We, therefore, examined whether
cytochrome c was released from the mitochondria during HMBA-
mediated death. Cytochrome c was present in all cytosolic extracts
of P-gp1 and P-gp- CEM cells treated with HMBA(Figure 6A) but
was not detected in untreated control cells. In addition, HMBA-
induced cytochrome c release was caspase-independent as it was
not inhibited by addition of ZVAD-fmk (Figure 6A). These results
were conﬁrmed by confocal microscopy on cells treated as above
and stained by immunoﬂuorescence for mitochondrial and cyto-
solic cytochrome c (data not shown).
It has been reported that HMBA induces a reduction in the
levels of the anti-apoptotic protein Bcl-2; however, the mechanism
of Bcl-2 down-regulation was not investigated.29 To examine the
affects of HMBA on Bcl-2 levels in P-gp1 and P-gp- cells, lysates
from CEM cells treated with ZVAD-fmk or control inhibitor
ZFA-fmk and HMBAwere analyzed for Bcl-2 byWestern analysis.
As shown in Figure 6B, treatment with HMBA resulted in a
caspase-independent reduction of Bcl-2. The decrease in Bcl-2
levels was speciﬁc as the levels of other proteins such as a-tubulin
(Figure 6B) and caspase-8 (Figure 5A) were unchanged.These data
indicate that HMBA induces a caspase-independent decrease in
Bcl-2 protein levels in P-gp1 and P-gp- cells with concomitant
release of cytochrome c from the mitochondria to the cytosol.
Overexpression of Bcl-2 inhibits HMBA-induced release of
cytochrome c and apoptosis
To further investigate the role of Bcl-2 in HMBA-induced cell
death, we examined the effects of overexpression of Bcl-2 in CEM
cells treated with HMBA. CEM cells overexpressing human Bcl-2
and parental CEM cells were treated with 10 mmol/L HMBA for
24-72 hours, and cell death was determined by trypan blue
exclusion (Figure 7A). After just 24 hours of treatment with 10
mmol/L HMBA, parental CEM cells underwent apoptosis (Figure
7A); however, Bcl-2 overexpressing cells were protected against
HMBA-induced apoptosis at concentrations from 10 mmol/L
(Figure 7A) to 30 mmol/Lfor as long as 72 hours (data not shown).
Clonogenic assays were performed on cells treated for 72 hours
with 0-15 mmol/LHMBA.As illustrated in Figure 7B, CEM-Bcl-2
cells formed signiﬁcant numbers of colonies at HMBA concentra-
tions as high as 15 mmol/L. These ﬁndings are consistent with an
earlier report that overexpression of Bcl-2 inhibits HMBA-
mediated cell death.29 In addition, cytochrome c was detected in
Figure 4. Hexamethylene bisacetamide (HMBA)-induced caspase-independent
cell death. CCRF (A, C) andA7 (B, D) CEM cells were treated with 10 mmol/LHMBA
or 5 ng/mLvincristine (Vin) for 48 hours. In some wells, cells were pre-incubated for 4
hours with 40 µmol/L ZFA-fmk or ZVAD-fmk. Cells were assayed by trypan blue
exclusion as described in ‘‘Materials and methods’’ (A, B) or were stained with
Hoechst 33 258 and visualized by confocal microscopy and scored for apoptotic
nucleiasdescribedin‘‘Materialsandmethods’’(C,D).Proteinlystateswereprepared
from cells treated as above and separated by SDS-PAGE. Western blots were
performed using polyclonal anti-PARP antibody (e). The active 118-kD and inactive
89-kD forms of PARP are indicated.
Figure 5. Hexamethylene bisacetamide (HMBA)-stimulated activation of caspase 9. CCRF andA7 CEM cells were treated with (A) 0-15 mmol/LHMBAfor 72 hours or (B)
100 ng/mL anti-Fas antibody (CH-11) for 12 hours. Protein lystates were separated by SDS/PAGE, and Western blots were performed using anti-caspase-3 (Caspase 3),
anti-caspase-8 monoclonal antibody (Caspase 8), and anti-caspase-9 polyclonal antibody (Caspase 9). The inactive (pro) and active (cleaved) forms of caspases-3, -8, and -9
are indicated. Nonspeciﬁc protein bands are denoted by an asterisk.
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mmol/L HMBA but was not present in lysates from CEM-Bcl-2
cells treated in the same manner (Figure 7C), illustrating that the
overexpression of Bcl-2 can completely block HMBA-mediated
cytochrome c release.
Discussion
P-gp-expressing, MDR T-cell leukemia, and colon carcinoma cell
lines were shown to undergo cell death induced by HMBA, a potent
differentiation agent of some hemopoietic cell lineages. P-gp1 and
P-gp- cells treated with HMBA displayed classical morphological
changes consistent with apoptosis, including chromatin condensa-
tion, DNA fragmentation, and membrane damage. Nuclear events,
such as DNA fragmentation and chromatin condensation induced
by HMBA treatment, were dependent on activation of caspases.
However, in the absence of caspase activation, HMBA still
mediated a decrease in Bcl-2 protein levels, cytochrome c release,
cell membrane damage, and subsequent cell death. Although
HMBA could activate caspases such as caspase-9 in both P-gp1
and P-gp- cells, consistent with our previous ﬁndings, activation of
caspase-3 was inhibited in P-gp1 cells. In addition, we have now
established that P-gp can affect activation of caspase-8 following
ligation of cell surface Fas.We have previously shown that addition
of P-gp-inhibitory antibodies MRK-16 or UIC2, or pharmacologi-
cal inhibitor verapamil, can allow the Fas-mediated activation of
caspase-3 in the same P-gp-positive cells used in this study,4,5
demonstrating that functional P-gp is affecting caspase-3 activation
and there are not endogenous inhibitors of caspases in P-gp-
expressing cells. We have demonstrated that HMBA activates two
death-inducing pathways (Figure 1): (i) a caspase-dependent
pathway that mediates nuclear apoptotic events and (ii) a caspase-
independent cell death pathway involving a decrease in Bcl-2
protein levels, mitochondrial damage, and cytochrome c release
that could be inhibited by the overexpression of Bcl-2. To date,
few examples of caspase-independent death stimuli have been
described, and this mechanism of cell death remains poorly
understood. Those stimuli which have been described to induce
caspase-independent cell death include CTL granule proteins,19
viral proteins,40 anti-CD2,20 gangliosides,41 staurosporine,20,21 and
the Bcl-2 family member Bax.42 HMBA appears to be the ﬁrst
chemotherapeutic drug shown to induce this novel form of
cell death.
We have previously reported that caspase-3 activation induced
by Fas ligation was inhibited in P-gp-expressing cells. We demon-
strate here that the cleavage of the upstream activator caspase-8 is
also inhibited in P-gp-expressing cells. Surprisingly, caspase-9 was
activated in both P-gp1 and P-gp- cells treated with HMBA,
indicating that P-gp may not act as a universal caspase inhibitor.
The fact that PARPwas cleaved in both P-gp1 and P-gp- CEM cells
treated with HMBAfurther suggests that ‘‘effector’’caspases other
than caspase-3 may be active in P-gp1 cells, such as caspase-7, or
that active caspase-9 might directly cleave PARP. Indeed, it has
been demonstrated that MCF-7 cells that lack functional caspase-3
still cleave PARP on addition of an apoptotic stimulus such as
TNF.43 Taken together, these data strongly suggest that P-gp may
only offer protection against cell death stimuli that rely on
activation of caspase-8, such as receptor-mediated cell death and
certainchemotherapeuticdrugsthatrequireactivationofcaspases-8
and -3 without ligation of cell surface Fas.44 Therefore, cell death
stimuli that utilize the mitochondria-mediated death pathway,
resulting in cytochrome c release and activation of caspase-9, may
be more effective in the treatment of MDR tumors. It is interesting
to note that P-gp1 cells treated with HMBA displayed a reduction
in DNA fragmentation compared with parental P-gp- cell lines and
that caspase inhibitors were more effective in blocking DNA
fragmentation in P-gp1 cells. It is tempting to speculate that this
phenomenon is due to the observed effect of P-gp on caspase-8 and
-3 activation (4,5 and this study), therefore resulting in an overall
decrease in activation of a number of different caspases. The
molecular mechanisms underpinning P-gp-mediated inhibition of
caspase-8 and -3 activation are not known and are currently under
investigation in our laboratory.
These data further conﬁrm our recent studies4,5 demonstrating
that P-gp cannot inhibit caspase-independent cell death.As with the
CTL granule proteins perforin/granzyme B,19 HMBA-induced cell
A B
Figure 6. Hexamethylene bisacetamide (HMBA) stimulates the release of
mitochondrial cytochrome c and loss of Bcl-2. (A) Cytosolic extracts from CCRF
andA7 CEM cells either untreated or treated with 10 mmol/LHMBAfor 72 hours were
separated by SDS/PAGE, and Western blots were performed using anti-cytochrome
c monoclonal antibody (mAb) that migrates at approximately 15 kd. The same blots
were reprobed with anti-a-Tubulin mAb denoted by a band of approximately 50 kd. In
some wells, cells were pre-incubated for 4 hours with 40 µmol/L ZFA-fmk or
ZVAD-fmk. (B) CCRF and A7 CEM cells were either untreated or treated with 10
mmol/L HMBA for 72 hours. In some wells, cells were pre-incubated for 4 hours with
40 mmol/L ZFA-fmk or ZVAD-fmk. Protein lystates were separated by SDS/PAGE,
and Western blots were performed using anti-Bcl-2 mAb that detects a speciﬁc band
of approximately 28 kd. The same blots were reprobed with anti-a-Tubulin mAb seen
migrating as a 50-kD protein.
Figure 7. Overexpression of Bcl-2 inhibits hexamethylene bisacetamide (HMBA)-mediated cell death. (A) CEM and CEM-Bcl-2 cells were cultured with 10 mmol/L
HMBAfor 72 hours, and cell death was assayed by trypan blue exclusion.These data were calculated as the mean6 SE of duplicate samples and are representative of at least
three separate experiments. (B)After incubation with 0, 1, 5, 7.5, 10, and 15 mmol/LHMBAfor 72 hours, cells were plated out in soft agar. Colonies were scored after 7 days in
culture as described in ‘‘Materials and methods.’’ (C) Cytosolic lysates from CEM (lanes 1-2) or CEM-Bcl-2 (lanes 3-4) cells either untreated (lanes 1 and 3) or treated for 72
hours with 10 mmol/LHMBA(lanes 2 and 4) were separated by SDS/PAGE and Western blotted for cytochrome c (15-kD protein) and then a-Tubulin (50-kD protein).
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Moreover, HMBA-induced cytochrome c release was independent
of active caspases. Together these data support the concept that the
disruption of the mitochondria membrane and subsequent release
of mitochondrial proteins may be necessary to induce caspase-
independent cell death.19,21,44 It is not known how HMBAmediates
the release of cytochrome c from the mitochondria. Whether
HMBA directly acts on the mitochondrial membrane and sup-
presses the membrane potential or indirectly enables cytochrome c
release by reducing Bcl-2 levels remains to be elucidated. Because
Bcl-2 had such an overwhelming inhibitory affect on HMBA-
mediated cell death, it is likely that other pro-apoptotic Bcl-2
family members are central to this pathway. However, clearly not
all chemotherapeutic agents function via this pathway. For ex-
ample, Flavopiridol, which is a candidate drug for the treatment of
chronic lymphocytic leukemia, induces cell death that correlates
with cleavage and activation of caspase-3, but no changes in the
levels of Bcl-2 were detected.45 Thus, the molecular events that lie
between HMBAtreatment and cytochrome c release have yet to be
elucidated. Other pro-apoptotic Bcl-2 family members, such as Bax
or Bad, or the recently identiﬁed apoptosis-inducing factor,13 which
has been shown to induce apoptosis in a caspase-independent
manner, may be more directly involved. We believe the pro-
apoptotic Bcl-2 family member Bid is not likely to be involved in
this mechanism of cell death since HMBAfailed to cleave Bid to its
p15 active subunit, whereas Fas ligation in CEM cells resulted in
Bid cleavage (data not shown).As Bid is known to be cleaved to its
active subunits by active caspase-8,16,17 the lack of Bid cleavage is
consistent with the fact that caspase-8 was not activated during
HMBA-mediated cell death.
We demonstrated that HMBAcan induce apoptosis or cell cycle
arrest in a cell-type speciﬁc manner using the chemotherapeutic
drugdosesusedinthisstudy.CEM/A7T-celllinesandLoVo/LoVo-
adr colon cell lines were sensitive to HMBA-induced cell death,
whereas the K562/KVIN erythroleukemia cells were arrested in the
G1 phase of the cell cycle with no apparent induction of apoptosis.
It is interesting to note that the CEM-Bcl-2 cells that were resistant
to HMBA-induced cell death underwent a G1 arrest when incu-
bated in 20-30 mmol/L HMBA. These results indicate that the
relative levels of the anti-apoptotic Bcl-2 family of proteins may
dictate whether a cell undergoes growth arrest or apoptosis
following exposure to HMBA, independent of P-gp expression. A
link between expression of Bcl-2 proteins and cell cycle regulation
has been previously hypothesized based on the close correlation
between cell cycle arrest in Go/G1 and upregulated expression of
the anti-apoptotic protein Bcl-XL in murine F-MEL erythroleuke-
miacellsinducedtoundergoterminaldifferentiationwithDMSO.46
Our results suggest that a more effective way to treat P-gp1
MDR tumors may hinge on the selection of drugs that are capable
ofinducingcaspase-independentapoptosisviamitochondrialmem-
brane disruption and do not require activation of caspases central to
the receptor-mediated cell death pathway. Although HMBA has
limited value in the clinic because of the high dosage required
(millimolar blood levels) and toxic side effects (thrombocytope-
nia),26 we are currently testing more potent second-generation
hybrid polar compounds47 for their effectiveness in inducing
apoptosis in P-gp-expressing MDR tumor cells. Future drug design
for the most effective treatment of P-gp1 MDR tumors could,
therefore, focus on agents that meet two criteria: (i) They cannot be
effluxed by P-gp, and (ii) they do not rely on the activation of
caspasestoinducecelldeath.Thus,thedevelopmentofchemothera-
peutic reagents that function in a similar manner to HMBA to
perturb the mitochondrial membrane, mediate the release of
cytochrome c, and induce caspase-independent cell death may lead
to improved outcomes in the treatment for MDR tumors.
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